NANEXA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.662 SEK | +5.41% |
|
-17.04% | -46.18% |
| Apr. 16 | Nanexa AB Announces Approval of Clinical Trial Application for NEX-22 Study Delayed | CI |
| Mar. 08 | Transcript : Nanexa AB - Special Call |
| Sales 2024 * | 71.3M 6.53M | Sales 2025 * | 69.5M 6.37M | Capitalization | 89.83M 8.23M |
|---|---|---|---|---|---|
| Net income 2024 * | 16M 1.47M | Net income 2025 * | -4M -366K | EV / Sales 2024 * | 0.34 x |
| Net cash position 2024 * | 65.5M 6M | Net cash position 2025 * | 82M 7.51M | EV / Sales 2025 * | 0.11 x |
| P/E ratio 2024 * |
16.6
x | P/E ratio 2025 * |
3.01
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.75% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nanexa AB
More press releases
| 1 day | +5.41% | ||
| 1 week | -17.04% | ||
| Current month | -14.69% | ||
| 1 month | -15.56% | ||
| 3 months | -39.82% | ||
| 6 months | -33.67% | ||
| Current year | -46.18% |
1 week
0.60
0.82
1 month
0.600.89
Current year
0.601.45
1 year
0.604.10
3 years
0.6011.10
5 years
0.6015.40
10 years
0.6016.09
| Managers | Title | Age | Since |
|---|---|---|---|
Mårten Rooth
FOU | Founder | 47 | 06-12-31 |
Anders Johansson
FOU | Founder | 48 | 06-12-31 |
David Westberg
CEO | Chief Executive Officer | 64 | 15-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 75 | 20-06-01 | |
| Director/Board Member | 69 | 22-12-31 | |
| Corporate Officer/Principal | 62 | 14-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.662 | +5.41% | 285,316 |
| 24-04-18 | 0.628 | -1.26% | 262,378 |
| 24-04-17 | 0.636 | -6.19% | 1,534,097 |
| 24-04-16 | 0.678 | -15.25% | 1,904,455 |
| 24-04-15 | 0.8 | +0.25% | 68,264 |
Delayed Quote Nasdaq Stockholm, April 19, 2024 at 10:53 am EDT
More quotes
Nanexa AB is a Sweden-based company engaged in the drug delivery systems industry. The Company specializes in the nanotechnology and research and development in life science. Its products portfolio is comprised of PharmaShell, a drug delivery system that allows for targeting and dosing of drugs; antifungal coating, a system that protects medical products from the in-growth of fungi; and low-friction coating for peripheral venous catheters.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -46.18% | 7.8M | |
| -38.08% | 132M |
- Stock Market
- Equities
- NANEXA Stock
